RecruitingNCT07597122

MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK

MIRSEP - MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK

Sponsor

Insel Gruppe AG, University Hospital Bern

Enrollment

56 participants

Start Date

Jun 1, 2026

Study Type

OBSERVATIONAL

Conditions

Sepsis and septic shock

Summary

Sepsis-induced immunosuppression (SIS) is a common complication in patients with septic shock. Reduced expression of Human leukocyte antigen isotype DR (HLA-DR) on circulating monocytes is a marker for SIS and correlates with risk of secondary infections and mortality. The miRSep study aims to improve the understanding of early microRNA (miRNA) mediated changes in HLA-DR on monocytes in patients with septic shock.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with sepsis and septic shock. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.